Arrowhead Pharma (ARWR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 09/30
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 75,253 | 73,737 | 264,033 | 256,472 | 27,767 |
| Gross Profit | 75,253 | 73,737 | 264,033 | 256,472 | 27,767 |
| Operating Expenses | 245,346 | 214,997 | 223,224 | 212,366 | 193,317 |
| Operating Income | -170,093 | -141,260 | 40,809 | 44,106 | -165,550 |
| Interest Expense | 24,562 | 23,846 | 22,505 | 21,694 | 24,382 |
| Other Income | 15,750 | 27,541 | 9,967 | 13,709 | 10,843 |
| Pre-tax Income | -178,905 | -137,565 | 28,271 | 36,121 | -179,089 |
| Income Tax | 11 | 7 | 29 | 20,000 | -437 |
| Net Income Continuous | -178,916 | -137,572 | 28,242 | 16,121 | -178,652 |
| Minority Interests | 15,364 | -4,840 | -2,569 | 39,871 | -3,411 |
| Net Income | $-194,280 | $-132,732 | $30,811 | $-23,750 | $-175,241 |
| EPS Basic Total Ops | -1.36 | -0.93 | 0.22 | -0.14 | -1.26 |
| EPS Basic Continuous Ops | -1.25 | -0.97 | 0.21 | 0.16 | -1.28 |
| EPS Diluted Total Ops | -1.36 | -0.93 | 0.22 | -0.11 | -1.26 |
| EPS Diluted Continuous Ops | -1.25 | -0.97 | 0.20 | 0.18 | -1.28 |
| EPS Diluted Before Non-Recurring Items | N/A | -0.93 | 0.22 | -0.18 | -1.26 |
| EBITDA(a) | $-164,275 | $-136,750 | $47,199 | $49,248 | $-161,084 |